Centocor ( CNTO ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO )

CNTO 0.00001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Henry Niman who wrote (70)	4/5/1997 2:06:00 AM
From: Miljenko Zuanic	of 965

Hanry, and other CNTO followers: Maybe you can help me. Today press release is completion of the one of small series PII CenTNF (cA2) trials for Crohn's, NOT a P III. This trials is for specific Crohn's subgroup: open fistulae. Centocor intend to initiate large P III trials for Crohn's and RA in 2Q 97 (10K 96). Trials should last from 15-18 months, three months for data collection and analysis, two months for NDA preparation, 6-8 months for review and recommendation, two months for FDA approval, one month for market clearing/labeling. All together, if OK, is 30-34 months. How can Eric Hecht from Morgan Stanley expect launch of CenNTF in 98? Am I missing something? I am the ISIP investor (Honorable CNTO shareholders, do not throw fire on me!) and I am trying to value CNTO chimeric anti-TNF for Crohn's and RA. Thanks in advance. mz

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next